Verition Fund Management’s Bio-Techne TECH Stock Holding History

Verition Fund Management’s Portfolio TECH Stock Details TECH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$51M	Buy	+721,900	New	+$39M	0.26%	51

Other funds holding TECH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Verition Fund Management's TECH Position: Q2 2026 in Review

Verition Fund Management increased its Bio-Techne (TECH) stake by 720% in Q2 2026, buying an estimated $20.8M and bringing the position to 438,746 shares worth $31M. The position accounts for 0.16% of the portfolio, ranked #131.

Verition Fund Management first reported a position in TECH in Q1 2015 and has held it in 26 quarters since. 596 funds tracked by Wall St. Rank hold TECH as of Q2 2026.

Verition Fund Management held 438,746 shares of Bio-Techne worth $31M as of Q2 2026.
Verition Fund Management bought 385,227 Bio-Techne shares in Q2 2026, an estimated $20.8M.
Bio-Techne made up 0.16% of Verition Fund Management's portfolio in Q2 2026, its #131 holding.
Verition Fund Management first reported a position in Bio-Techne in Q1 2015 and has held it in 26 quarters since.
596 funds tracked by Wall St. Rank held Bio-Techne as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.